Publication:
De novo EHMT2 variants cause an autosomal dominant EHMT2-related Kleefstra syndrome via loss of G9a methyltransferase activity.

dc.contributor.authorHnízda, Aleš
dc.contributor.authorMartinez-Delgado, Beatriz
dc.contributor.authorSánchez-Ponce, Diana
dc.contributor.authorAlonso, Javier
dc.contributor.authorAmiel, Jeanne
dc.contributor.authorAttie-Bitach, Tania
dc.contributor.authorBada-Navarro, Ariadna
dc.contributor.authorBaladron-Jimenez, Beatriz Isabel
dc.contributor.authorBermejo-Sanchez, Eva
dc.contributor.authorBrinsa, Vítězslav
dc.contributor.authorBuková, Ivana
dc.contributor.authorCazorla-Calleja, Rosario
dc.contributor.authorČervenková, Sylvie
dc.contributor.authorChow, Shanshan
dc.contributor.authorDušek, Petr
dc.contributor.authorFedosieieva, Olha
dc.contributor.authorFernandez-Prieto, Marta
dc.contributor.authorGhosh, Sourav
dc.contributor.authorGomez-Mariano, Gema Maria
dc.contributor.authorGřegořová, Andrea
dc.contributor.authorHamilton, Mark James
dc.contributor.authorHartmannová, Hana
dc.contributor.authorHernandez-SanMiguel, Esther
dc.contributor.authorHerrero-Matesanz, Marina
dc.contributor.authorHodaňová, Kateřina
dc.contributor.authorKádek, Alan
dc.contributor.authorKerkhof, Jennifer
dc.contributor.authorKleefstra, Tjitske
dc.contributor.authorLacombe, Didier
dc.contributor.authorLevy, Michael A
dc.contributor.authorLopez-Martin, Estrella
dc.contributor.authorLyse, Ruaud
dc.contributor.authorMan, Petr
dc.contributor.authorMarin-Reina, Purificacion
dc.contributor.authorMacnamara, Ellen F
dc.contributor.authorMcConkey, Haley
dc.contributor.authorMelenovská, Petra
dc.contributor.authorMirela Mielu, Lidia
dc.contributor.authorMoore, David
dc.contributor.authorSteiner Mrázová, Lenka
dc.contributor.authorMusilová, Karolína
dc.contributor.authorNeffeová, Kristýna
dc.contributor.authorNickl, Petr
dc.contributor.authorPajuelo Reguera, David
dc.contributor.authorPavlíková, Martina
dc.contributor.authorPavlovičová, Lea
dc.contributor.authorPosada De la Paz, Manuel
dc.contributor.authorProcházka, Jan
dc.contributor.authorPysanenko, Kateryna
dc.contributor.authorRamos-Del Saz, Sheila
dc.contributor.authorRots, Dmitrijs
dc.contributor.authorRzasa, Jessica
dc.contributor.authorSedláček, Radislav
dc.contributor.authorStránecký, Viktor
dc.contributor.authorŠpoutil, František
dc.contributor.authorTedder, Matthew L
dc.contributor.authorThompson, Louise
dc.contributor.authorTifft, Cynthia J
dc.contributor.authorTran Mau-Them, Frederic
dc.contributor.authorTrešlová, Helena
dc.contributor.authorVitobello, Antonio
dc.contributor.authorHilton, Sarah
dc.contributor.authorCampbell, Christopher
dc.contributor.authorBanka, Siddharth
dc.contributor.authorJirák, Daniel
dc.contributor.authorSadikovic, Bekim
dc.contributor.authorSikora, Jakub
dc.contributor.authorKmoch, Stanislav
dc.contributor.authorBarrero, Maria J
dc.contributor.authorNosková, Lenka
dc.contributor.funderUnión Europea. Comisión Europea
dc.contributor.funderFundación Inocente-Inocente
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)
dc.date.accessioned2026-11-03T13:38:31Z
dc.date.available2026-11-03T13:38:31Z
dc.date.issued2026-07-01
dc.description.abstractEHMT1 and EHMT2 genes encode human euchromatin histone lysine methyltransferase 1 and 2 (EHMT1 alias GLP; EHMT2 alias G9a) that form heteromeric GLP/G9a complexes with essential roles in epigenetic regulation of gene expression. While EHMT1 haploinsufficiency has been established as the cause of Kleefstra syndrome 1, the pathogenesis of G9a dysfunction in human disease remains largely unknown. We identified seven de novo EHMT2 variants in patients with clinical presentation, episignatures, histone modifications and transcriptomic profiles similar to those of Kleefstra syndrome 1. In vitro studies reveal that these variants encode for structurally stable G9a proteins that are catalytically incompetent due to aberrant interactions either with histone H3 tail or with S-adenosylmethionine. Heterozygous mice carrying a patient-derived variant exhibit growth retardation, facial/skull dysmorphia and aberrant behavior. Here we report pathogenic EHMT2 variants that likely exert dominant-negative effect on GLP/G9a complexes and thus genocopy the EHMT1 haploinsufficiency via a distinct molecular mechanism, defining an autosomal dominant EHMT2-related Kleefstra syndrome.
dc.description.peerreviewedSí
dc.description.sponsorshipThis work was supported from the project MULTIOMICS_CZ (Program Johannes Amos Comenius, Ministry of Education, Youth and Sports of the Czech Republic, ID Project CZ.02.01.01/00/23_020/0008540) – Co-funded by the European Union. L.N., A.H., and J.S. were supported by the project National Institute for Neurological Research (Program EXCELES, ID Project No. LX22NPO5107) - Funded by the European Union – Next Generation EU and by institutional program UNCE/MED/007 of Charles University in Prague. A.H. was funded from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 101003406 (HIPPOSTRUCT). AH, AK, VB and LN were funded by the grant 26-21355S from the Czech Science Foundation. L.N., J.S. and S.K. were supported by grants NU23-07-00281 and NW24-04-00067 from the Ministry of Health of the Czech Republic. L.N., V.S. and S.K thank the National Center for Medical Genomics (LM2023067) for WES analyses. A.K. acknowledges funding by the European Union’s ERA fellowship (2D-TOPMASS, grant 101090276). The work was further supported by the grants from the Spanish Ministry of Science and Innovation PID2021-128087OB-I00 by MCIN /AEI /10.13039/501100011033 / FEDER, UE to M.J.B, Fundación Inocente grant number FII2024-125 and grant AESI PT20CIII/00009 (ISCIII Platform of Biobanks and Biomodels PT-20/23) from the Spanish National Institute of Health Carlos III. Funding was also partially provided by the Genome Canada and the Ontario Genomics Institute Genomics Applications Partnership Program Grant (OGI-188). Several co-authors are also members of the European Reference Network ITHACA. We further acknowledge the Solve-RD project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 779257.We further acknowledge CMS-Biocev (“Biophysical techniques, Crystallization, Diffraction, Structural mass spectrometry”) of CIISB, Instruct-CZ Center, supported by MEYS CR (LM2023042) and European Regional Development Fund-Project „UP CIISB“ (No. CZ.02.1.01/0.0/0.0/18_046/0015974). This study used tools provided through the RD-Connect GPAP, which received funding originally from the European Union Seventh Framework Program (FP7/2007-2013) under grant agreement No. 305444. This study has also been delivered through the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Center (NIHR203308). S.B. acknowledges the support of the MRC Epigenomics of Rare Diseases (EpiGenRare) Node (MR/Y008170/1). D.J. acknowledges the financial support from the Ministry of Health of the Czech Republic (MH CZ-DRO, Institute for Clinical and Experimental Medicine IKEM, IN 00023001).
dc.format.number1
dc.format.volume17
dc.identifier.citationHnízda, A., Martinez-Delgado, B., Sanchez-Ponce, D. et al. De novo EHMT2 variants cause an autosomal dominant EHMT2-related Kleefstra syndrome via loss of G9a methyltransferase activity. Nat Commun 17, 8203 (2026). https://doi.org/10.1038/s41467-026-74987-w.
dc.identifier.doi10.1038/s41467-026-74987-w
dc.identifier.e-issn2041-1723
dc.identifier.journalNature communications
dc.identifier.pubmedID42386776
dc.identifier.urihttps://hdl.handle.net/20.500.12105/27798
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.isbasedonhttps://proteomecentral.proteomexchange.org/ui?pxid=PXD079241
dc.relation.isbasedonhttps://ega-archive.org/studies/EGAS50000001637
dc.relation.isbasedonhttps://doi.org/10.5281/zenodo.19630380
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2021-128087OB-I00/ES/MOLELOS Y MECANISMOS EN ENFERMEDADES ULTRA RARAS CON BASE EPIGENETICA/
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI-FEDER//501100011033///
dc.relation.projectIDinfo:eu-repo/grantAgreement/Fundación Inocente//FII2024-125///
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/AESI/PT20CIII%2F00009///
dc.relation.publisherversionhttps://doi.org/10.1038/s41467-026-74987-w
dc.repisalud.centroISCIII::Instituto de Investigación de Enfermedades Raras (IIER)
dc.repisalud.institucionISCIII
dc.rights.accessRightsopen access
dc.rights.licenseAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.meshAnimals
dc.subject.meshChromosome Deletion
dc.subject.meshChromosomes, Human, Pair 9
dc.subject.meshCraniofacial Abnormalities
dc.subject.meshFemale
dc.subject.meshHand Deformities, Congenital
dc.subject.meshHaploinsufficiency
dc.subject.meshHeart Defects, Congenital
dc.subject.meshHistocompatibility Antigens
dc.subject.meshHistone-Lysine N-Methyltransferase
dc.subject.meshHistones
dc.subject.meshHumans
dc.subject.meshIntellectual Disability
dc.subject.meshMale
dc.subject.meshMice
dc.titleDe novo EHMT2 variants cause an autosomal dominant EHMT2-related Kleefstra syndrome via loss of G9a methyltransferase activity.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication1ddea53d-8bbc-4196-82a6-1f6b8ea3a92b
relation.isAuthorOfPublicationb0355d3e-36ca-4aab-a60a-9cf49c62bda4
relation.isAuthorOfPublication7416f724-f758-4723-8e95-ca2ff70ee53c
relation.isAuthorOfPublication16ca30ec-854c-4770-931e-e7d9ea71369a
relation.isAuthorOfPublication5764d316-caf4-47a6-b03f-4cfdc5b2e892
relation.isAuthorOfPublication9b9ff7e4-de3b-439a-b53a-dd659936a88c
relation.isAuthorOfPublicationd0ee7849-1683-4c6e-b977-2a93cf579641
relation.isAuthorOfPublicationd8e72207-5535-4159-833e-6d203a600e90
relation.isAuthorOfPublication7c941dce-7293-4477-b341-511263e217e9
relation.isAuthorOfPublication6db924bf-24e0-4299-8c78-50337deed109
relation.isAuthorOfPublicationc474ba31-7f20-4966-a77e-34f9bf4f3602
relation.isAuthorOfPublication75b3e5cf-ce99-4092-a6b0-8ba38b493bd8
relation.isAuthorOfPublication.latestForDiscovery1ddea53d-8bbc-4196-82a6-1f6b8ea3a92b
relation.isFunderOfPublication639cecfa-9455-4e7f-9f65-9ece17a878f0
relation.isFunderOfPublication77207b4b-da6c-45c7-80ac-ea685be4b26b
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication1aef4c3b-1ee5-4534-83b4-3f3811c67280
relation.isFunderOfPublication.latestForDiscovery639cecfa-9455-4e7f-9f65-9ece17a878f0
relation.isPublisherOfPublicationb35c2080-c7d1-4e7c-95ea-1d4c7d394078
relation.isPublisherOfPublication.latestForDiscoveryb35c2080-c7d1-4e7c-95ea-1d4c7d394078

Files

Original bundle

Now showing 1 - 3 of 3
Loading...
Thumbnail Image
Name:
DeNovoEHMT2Variants_2026.pdf
Size:
5.66 MB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
Figures_DeNovoEHMT2Variants_2026.zip
Size:
1.64 MB
Format:
Loading...
Thumbnail Image
Name:
Supplementary_DeNovoEHMT2Variants_2026.zip
Size:
198.28 MB
Format: